

## FORM 7 MONTHLY PROGRESS REPORT

**Name of Listed Issuer:** AREV Nutrition Sciences Inc. (“AREV” or the “Issuer”)

**Trading Symbol:** AREV

**Number of Outstanding Listed Securities:** 34,234,209

**Date:** July 2018

Report on Business:

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer, AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.

During the month of July, 2018 the Company is announce it has entered into an asset purchase and sale agreement (the “Acquisition Agreement”) dated July 3, 2018 with Matthew Harvey carrying on business under the branding “BC Bud Depot” (“BCBD”), subject to pending CSE approval, to acquire 100% of the assets under the BCBD brand in consideration for issuance of 9,500,000 common shares of the Company at a deemed price of \$0.50 per share and \$500,000, of which \$50,000 is payable in cash and \$450,000 is payable by way of a convertible debenture (the “Convertible Debenture”) issued by the Company accruing interest at 8% per annum, for an aggregate value of \$5,250,000. The outstanding principal amount and outstanding accruing interest of the Convertible Debenture shall be convertible into common shares of the Company at the price of \$0.50 per common share.

The BCBD assets comprises breeding methodologies for new cannabis strains available for license to licensed producers for replication and further processing activities and capabilities and technologies for the development of further breeding methodologies. The BCBD assets have a large collection of breeding methodologies developed over many years in the creation of a variety of marijuana strains. BCBD specializes in launching new

strains, generating initial interest and demand, and market testing based on public perception over time.

BCBD holds one of the world's largest seed banks and has won over 40 awards over the past 14 years since becoming the first Canadian company in history to win as Top Strain at international competition, in 2004 with BC God Bud.

BCBD has held the inside cover of High Times Magazine for the past ten years and remains among the most recognized names in cannabis genetics and breeding.

During the month of July 2018 the Company was pleased to announce that the Company has acquired, **DEUTSCHE MEDIZINAL CANNABIS UG, ("DMC")**, which becomes the Company's wholly owned German subsidiary. This purchase was strategic in that the procedure from the health ministry on granting production and distribution licenses for medical cannabis in Germany was halted by a court decision. As such, no licenses have been granted to any company in Germany, so far and the ministry will have to repeat the entire procedure for granting the licenses. At that time, DMC is one out of only 26 companies (of 118 that participated) which had been considered eligible by the ministry, at all. The acquisition is in consideration of an aggregate of \$18,000 euros paid to four vendors. Nils Rehmann, a director of the Company is one of the vendors and is considered to be a "related party" within the meaning of MI 61-101 Protection of Minority Security Holders in Special Transactions and such transaction is considered to be a "related party transaction" but is exempt from the valuation and minority shareholder approval requirements thereunder by virtue of the exemptions contained in sections 5.5(a) and 5.7(a) in that the fair market value of the consideration is less than 25% of the Company's market capitalization.

The company plans to utilize all of its extensive resources which include genetics, breeding, cultivation, extraction and a line of finished products including Bare Topicals and Cannamultion to build an integrated model that partners with LP's to grow its proprietary Genetics via off take agreements for extraction and conversion into proprietary ingredients to be used in its product formulations.

During the month of July 2018 the Company is pleased to announce that they reached a settlement with WGBC.

2. Provide a general overview and discussion of the activities of management.

During the month of July 2018, management worked with BCBD to close the asset purchase and sale agreement and with WGBC to reach a settlement. The Company continues to work to secure key strategic relationships.

**2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production**

**programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None.

- 3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None.

- 4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None.

- 6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None.

- 7. Describe any acquisitions by the Issuer dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None.

- 8. Describe the acquisition of new customers or loss of customers.**

None.

- 9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.**

None.

- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None.

**11. Report on any labour disputes and resolutions of those disputes if applicable.**

None.

**12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None.

**13. Provide details of any indebtedness incurred or repaid by the Issuer with the terms of such indebtedness together.**

None.

**14. Provide details of any securities issued and options or warrants granted.**

None.

**(1) State aggregate proceeds and intended allocation of proceeds.**

None.

**15. Provide details of any loans to or by Related Persons.**

None.

**16. Provide details of any changes in directors, officers or committee members.**

None.

**17. Discuss any trend which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

The trends and risks which are likely to impact the Issuer are discussed in the Issuer's financial statements (the "YE Financial Statements") and corresponding management's discussion and analysis (the "YE MD&A") for the year-ended December 31, 2017. The Q4 Financial Statements and YE MD&A are both available under the Issuer's profile on SEDAR at [www.sedar.com](http://www.sedar.com).


**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 11, 2018

Stephane Maher  
Name of Director or Senior Officer

  
Signature

Chief Executive Officer and Director Official Capacity

Issuer Details Name of Issuer AREV Nutrition Sciences Inc.	For Month End July, 2018	Date of Report 11/08/2018
Issuer Address Unit 2 – 9049 Shaughnessy Street		
City/Province/Postal Code Vancouver, BC V6P 6R9	Issuer Fax No. N/A	Issuer Telephone No. (608) 868 - 5013
Contact Name Denby Greenslade	Contact Position Corporate Secretary	Contact Telephone No. (604) 803-8439
Contact Email Address denby@arevnutrition.com	Web Site Address http://arevnutrition.com/	